Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Revelation Biosciences Inc
(NQ:
REVB
)
1.210
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Revelation Biosciences Inc
< Previous
1
2
Next >
Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds
August 21, 2024
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024
August 09, 2024
From
Revelation Biosciences, Inc.
Via
Business Wire
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
June 24, 2024
From
Revelation Biosciences, Inc.
Via
Business Wire
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
June 13, 2024
From
Revelation Biosciences, Inc.
Via
Business Wire
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
May 10, 2024
From
Revelation Biosciences, Inc.
Via
Business Wire
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
March 22, 2024
From
Revelation Biosciences, Inc.
Via
Business Wire
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
March 13, 2024
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference
March 12, 2024
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
March 04, 2024
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
February 13, 2024
From
Revelation Biosciences Inc.
Via
Business Wire
BioMedNewsBreaks – Revelation Biosciences Inc. (NASDAQ: REVB) Secures ~$6.2M in Public Offering
February 08, 2024
Via
Investor Brand Network
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
February 05, 2024
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
February 01, 2024
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
January 30, 2024
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024
January 23, 2024
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023
November 13, 2023
From
Revelation Biosciences, Inc.
Via
Business Wire
Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies
October 12, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference
October 04, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors
October 02, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023
August 11, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders
June 29, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal
June 12, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress
May 22, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress
March 30, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board
March 13, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference
March 06, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering
February 13, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering
February 09, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300
February 07, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective February 1, 2023 and Results of Special Meeting of Stockholders
January 31, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.